Comments on ICER’s February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”. Some of the concerns raised in the letter point out that the draft report utilizes unpublished or unreviewed presentations or papers as data sources. For example, one of the sources for the baseline population characteristics is a paper that was presented at a conference rather than published after peer review. We note that this data source was used for modeling the baseline population for one of the three treatments in the draft report, while the other two had their own citations – both published papers. Read Patients Rising’s full comments here.
Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.
